扁蒴藤素提高人食管鳞状细胞癌耐药细胞株ECA109/DDP的顺铂敏感性

doi:10.16352/j.issn.1001-6325.2026.09.1200

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (9): 1200-1206.doi: 10.16352/j.issn.1001-6325.2026.09.1200

扁蒴藤素提高人食管鳞状细胞癌耐药细胞株ECA109/DDP的顺铂敏感性

刘桂举, 袁威, 吕鼎霖, 韩倩倩, 梅家转^*, 张浩哲

郑州人民医院肿瘤内科,河南郑州 450000

收稿日期:2025-07-20 修回日期:2025-11-26 出版日期:2026-09-05 发布日期:2026-08-18
通讯作者: ^*mjzhuan@163.com
基金资助:
河南省医学科技攻关计划联合共建项目(LHGJ20230723)

Pristimerin sensitizes human esophageal squamous cell carcinoma cell strain ECA109/DDP to cisplatin

LIU Guiju, YUAN Wei, LYU Dinglin, HAN Qianqian, MEI Jiazhuan^*, ZHANG Haozhe

Department of Medical Oncology, People′s Hospital of Zhengzhou, Zhengzhou 450000, China

Received:2025-07-20 Revised:2025-11-26 Online:2026-09-05 Published:2026-08-18
Contact: ^*mjzhuan@163.com

摘要/Abstract

摘要： 目的探讨扁蒴藤素对食管鳞状细胞癌细胞系ECA109顺铂(DDP)敏感性的作用机制。方法 20 μg/mL DDP处理ECA109细胞,每2~3代递增药物浓度(40、80、100 μg/mL),持续3~6个月直至细胞在高浓度DDP(80 μg/mL)下稳定增殖,即获得DDP稳定耐药株ECA109/DDP。将ECA109/DDP细胞分为对照组(溶剂对照)、DDP(80 μg/mL)组、扁蒴藤素(1 μmol/L)组、扁蒴藤素(1 μmol/L)+DDP(80 μg/mL)组、扁蒴藤素(1 μmol/L)+DDP(80 μg/mL)+TGF-β激活剂(SRI-011381)(10 μmol/L)组。CCK-8法和集落形成实验检测细胞增殖;流式细胞测量术检测细胞凋亡;划痕实验、Transwell小室法分别检测细胞迁移、侵袭;Western blot检测细胞多药耐药相关蛋白1(MRP1)、P-糖蛋白(P-gp)、转化生长因子-β1(TGF-β1)、Smad4、CD44蛋白表达。结果与对照组相比,DDP组各指标差异无统计学意义,扁蒴藤素组A₄₅₀值、集落形成率、划痕愈合率、细胞侵袭数减少(P＜0.05);MRP1、P-gp、TGF-β1、Smad4、CD44蛋白表达降低,细胞凋亡率增加(P＜0.05);与DDP组、扁蒴藤素组相比,扁蒴藤素+DDP组A₄₅₀值、集落形成率、划痕愈合率、细胞侵袭数减少,MRP1、P-gp、TGF-β1、Smad4、CD44蛋白表达降低,细胞凋亡率增加(P＜0.05);与扁蒴藤素+DDP组相比,扁蒴藤素+DDP+SRI-011381组上述指标变化趋势相反(P＜0.05)。结论扁蒴藤素可通过抑制TGF-β/Smad通路增强ECA109/DDP细胞DDP敏感性。

关键词: 扁蒴藤素, 食管鳞状细胞癌, 顺铂, 化学药物治疗敏感性, 增殖

Abstract: Objective To investigate the mechanism by which pristimerin enhances cis-diamine dichloroplatinum/cisplatin(DDP) sensitivity of esophageal squamous cell carcinoma cell line ECA109. Methods ECA109 cells were treated with 20 μg/mL DDP, with drug concentrations incrementally increased (40, 80, 100 μg/mL) every 2-3 passages. After 3-6 months, stable DDP-resistant ECA109/DDP cells were obtained which proliferated in high DDP concentration environment (80 μg/mL). The ECA109/DDP cells were divided into the following groups: control, DDP (80 μg/mL), pristimerin (1 μmol/L), pristimerin (1 μmol/L)+DDP (80 μg/mL), and pristimerin (1 μmol/L)+DDP (80 μg/mL)+TGF-β activator (SRI-011381) (10 μmol/L). Cell proliferation was assessed by CCK-8 assay and colony formation test; Apoptosis was examined by flow cytometry; Migration and invasion were evaluated via scratch wound healing and Transwell assays, respectively. The protein expressions of multidrug resistance-associated protein 1 (MRP1), P-glycoprotein (P-gp), TGF-β1, Smad4, and CD44 were measured by Western blot. Results Compared with control group, there was no difference in various indicators in the DDP group(P＜0.05). While pristimerin group exhibited a decrease of A₄₅₀ values, colony formation rate, scratch healing rate, number of invasive cells. The protein level of MRP1, P-gp, TGF-β1, Smad4, and CD44 also decreased, along with increased apoptosis (P＜0.05). Compared with the DDP and pristimerin groups, the pristimerin+DDP group showed further reduction in A₄₅₀ values, colony formation rate, scratch healing rate, number of invasive cells, and protein level of MRP1, P-gp, TGF-β1, Smad4, and CD44, as well as increased apoptosis (P＜0.05). Compared with pristimerin+DDP group, pristimerin+DDP+SRI-011381 group showed an opposite trend in all the above indicators (P＜0.05). Conclusions Pristimerin enhances DDP sensitivity in ECA109/DDP cells by inhibition of TGF-β/Smad pathway.

Key words: pristimerin, esophageal squamous cell carcinoma, cisplatin, chemosensitivity, proliferation

中图分类号:

R735.1

刘桂举, 袁威, 吕鼎霖, 韩倩倩, 梅家转, 张浩哲. 扁蒴藤素提高人食管鳞状细胞癌耐药细胞株ECA109/DDP的顺铂敏感性[J]. 基础医学与临床, 2026, 46(9): 1200-1206.

LIU Guiju, YUAN Wei, LYU Dinglin, HAN Qianqian, MEI Jiazhuan, ZHANG Haozhe. Pristimerin sensitizes human esophageal squamous cell carcinoma cell strain ECA109/DDP to cisplatin[J]. Basic & Clinical Medicine, 2026, 46(9): 1200-1206.

参考文献 12

[1]	史铁伟, 李天柱, 周静, 等. 5-脂氧合酶激活蛋白抑制剂MK886对人食管癌细胞系增殖和凋亡的影响[J]. 基础医学与临床, 2022, 42:56-61.
[2]	Rai V, Abdo J, Agrawal DK. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers[J]. Int J Mol Sci, 2023, 24:3316. doi: 10.3390/ijms24043316.
[3]	Huang P, Sun LY, Zhang YQ. A hopeful natural product, pristimerin, induces apoptosis, cell cycle arrest, and autophagy in esophageal cancer cells[J]. Anal Cell Pathol (Amst), 2019, 2019:6127169. doi: 10.1155/2019/6127169.
[4]	Wang L, Lang B, Zhou Y, et al. Up-regulation of miR-663a inhibits the cancer stem cell-like properties of glioma via repressing the KDM2A-mediated TGF-β/SMAD signaling pathway[J]. Cell Cycle, 2021, 20:1935-1952.
[5]	李朝慧, 任本洪, 孙雪娇, 等. 顺铂耐药对食管癌细胞增殖、凋亡、迁移和血管生成的影响[J]. 中国病理生理杂志, 2017, 33:1-6.
[6]	于彬, 于勇, 时磊, 等. 扁蒴藤素对肝细胞癌细胞生物学行为及吉西他滨化疗敏感性的影响[J]. 中国普通外科杂志, 2023, 32: 221-230.
[7]	杜鹃, 刘媛, 杨倩, 等. 牛磺熊去氧胆酸通过TGF-β1/Smad3信号通路对高糖诱导的人脐静脉内皮细胞损伤的影响[J]. 贵州医科大学学报, 2025, 50:875-882.
[8]	Wang Y, Feng W, Wang X, et al. The multifaceted mechanisms of pristimerin in the treatment of tumors state-of-the-art[J]. Biomed Pharmacother, 2022, 154:113575. doi: 10.1016/j.biopha.2022.113575.
[9]	Feng M, Zhang A, Wu J, et al. Pristimerin induces noxa-dependent apoptosis by activating the FoxO3a pathway in esophageal squamous cell carcinoma[J]. Chin J Nat Med, 2025, 23:585-592.
[10]	Li Y, Zhou Z, Qu J, et al. Role of microRNA-4739 in enhancing cisplatin chemosensitivity by negative regulation of RHBDD2 in human cervical cancer cells[J]. Cell Mol Biol Lett, 2024, 29:20. doi: 10.1186/s11658-024-00532-6.
[11]	Jin S, Wang W, Xu X, et al. miR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer[J]. Acta Biochim Biophys Sin (Shanghai), 2024, 56:740-752.
[12]	Yu D, Shin HS, Lee YS, et al. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells[J]. Lab Invest, 2014, 94:1370-1381.

[1]	韩超, 孔为民, 宋丹. 过表达miR-130a-3p增强人宫颈癌细胞系Caski对放化疗的敏感性[J]. 基础医学与临床, 2026, 46(8): 1103-1108.
[2]	刘获晞, 黄柏添, 赵云焘, 张家洋, 吴文梅. 过表达组蛋白去乙酰化酶4抑制人结直肠癌细胞系的增殖及侵袭[J]. 基础医学与临床, 2026, 46(8): 1051-1058.
[3]	范文怡, 陈瑜炜, 郑翠婷, 吕佳蕊, 王亚南. Pifithrin-μ抑制TSC2突变肝癌细胞株增殖[J]. 基础医学与临床, 2026, 46(8): 1059-1067.
[4]	管晓星, 郭金鑫, 张朦, 贾超, 常艳, 张璇, 何乐建. 中心体蛋白89促进神经母细胞瘤细胞系体外增殖[J]. 基础医学与临床, 2026, 46(6): 836-844.
[5]	李志涛, 步雪峰, 张拥军, 孟娜娜, 夏磊洲. 法尼酯X受体通过负调控基质金属蛋白酶7抑制胰腺癌细胞增殖[J]. 基础医学与临床, 2026, 46(2): 250-255.
[6]	蔡原, 贾常莎, 王丽, 张兰方, 晏文. 罗格列酮抑制兔耳增生性瘢痕的形成[J]. 基础医学与临床, 2026, 46(11): 1501-1507.
[7]	程志坚, 王国毓, 贺西京, 翟静静, 王涛宁. 小鼠骨髓来源巨噬细胞原代培养中NG2表达及生物活性[J]. 基础医学与临床, 2026, 46(1): 1-4.
[8]	韦新闻, 温小军, 樊钊强, 劳锡峰, 张鲁青, 钟鸣. CircAPLP2通过调节miR-455-3p/STMN1轴抑制人结直肠癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2025, 45(9): 1208-1214.
[9]	安信, 贾麟, 马吾苏木·马木特, 黄志鹏, 卡哈尔曼·斯拉木, 热夏提·热合曼, 海日拉·吾拉木, 库尔班江·阿布力克木, 加素尔·巴吐尔. ANGPT1影响小鼠前列腺癌细胞系RM-1增殖、侵袭及血管生成[J]. 基础医学与临床, 2025, 45(9): 1165-1172.
[10]	邹庆波, 张国臣, 潘长景. 绞股蓝皂苷抑制人前列腺癌细胞系PC-3增殖、迁移和侵袭[J]. 基础医学与临床, 2025, 45(8): 1059-1065.
[11]	赵翠娟, 敖民, 武文博, 李妍华. 高脂饮食加重小鼠肠易激综合征肠屏障损伤[J]. 基础医学与临床, 2025, 45(8): 1022-1027.
[12]	田野, 何权, 王小娟. RPRD1B在人卵巢癌细胞系中高表达并促进肿瘤细胞增殖[J]. 基础医学与临床, 2025, 45(8): 1066-1072.
[13]	殷利军, 卜阳, 昂格勒玛, 宋琳琳. LncRNA HIF1A-AS1通过干预HIF1A促进胃癌细胞系增殖[J]. 基础医学与临床, 2025, 45(5): 627-636.
[14]	魏建新, 房彦乐, 鲁雨博, 高宇光, 郎兴, 李静涛, 马新生. 青蒿琥酯抑制肾母细胞瘤细胞系SK-NEP-1增殖和促进凋亡与自噬[J]. 基础医学与临床, 2025, 45(4): 493-498.
[15]	周晶, 屈苗. 上调miR-152抑制ox-LDL诱导的人血管平滑肌细胞增殖和迁移[J]. 基础医学与临床, 2025, 45(4): 486-492.

扁蒴藤素提高人食管鳞状细胞癌耐药细胞株ECA109/DDP的顺铂敏感性

Pristimerin sensitizes human esophageal squamous cell carcinoma cell strain ECA109/DDP to cisplatin

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 15

编辑推荐

Metrics

本文评价